I am thrilled to welcome Steve Paul to Between the Biotech Waves.With nearly 50 years of experience as a physician-scientist, Steve has made significant contributions to the fields of neuroscience, molecular neuropharmacology, and CNS drug ...

Today, I are excited to welcome Kent Rogers, the Chief Executive Officer of EveryONE Medicines. Kent brings a wealth of experience to his new role, having held executive leadership positions at renowned pharmaceutical companies as well as emerg...

Sound Bite with Bill Hicks looking at the market and financing in real time.

Welcome to a Between the Biotech Waves sound bite, a short podcast to provide insight into the rapidly changing biotech environment - I am pleased to welcome Paul Matteis Managing Director, Head of Therapeutics Equity Research in Biotech...

In this episode, I am thrilled to welcome Dan Lynch, an Executive Venture Partner at Google Ventures and a seasoned leader in the biotechnology sector.Since joining GV in 2021, Dan has partnered with life sciences CEOs and executives, provi...

In today's episode, I am honored to welcome Stanley Crooke, the founder and CEO of Ionis Pharmaceuticals the first and leading antisense oligonucleotide biotech and founder, CEO and Chair of N-Lorem, a not for profit entity developing ASOs for ...

Welcome to ‘Between the Biotech Waves,’ the podcast where we navigate the dynamic world of biotechnology and explore the minds driving its innovation. I’m your host, Nessan Bermingham, and today, we have a true visionary in the field, Peter Bar...

Now that JPM '25 is behind us, where the weather was great but the mood was somber, back to podcasting!Welcome back to 'Between the Biotech Waves,' the podcast where we explore the frontiers of biotechnology and the remarkable individuals d...

Welcome back to Between the Biotech Waves. I am sorry for the lack of episodes over the past few months, unfortunately life threw me a curve ball that I have been taking care of but now back and ready to go!Today it gives me great pleasu...

Today I am talking to Eliot Forster xCEO of F-star Therapeutics.Eliot was at helm of the company as they reversed merged into Springbank Pharmaceuticals & through the recently announced acquisition by Sino Biopharma, a transaction that ...

Today we have an unusual (& long) podcast where we talk to key members of the Triplet Therapeutics management team. Triplet was founded to develop antisense oligonucleotides targeting the DNA damage response pathway that has been implicated...

Today we are talking to Tim Yu. Tim is attending physician at the division of genetics and genomics at Boston Children’s Hospital and assoc prof of Pediatrics at Harvard Medical School. The scope of work that Tim does is well beyond what can b...

Today we are talking to Barry Greene, CEO of Sage Therapeutics. Barry has had an amazing career spanning over 30 years in the biotech industry. Prior to Sage Barry was President of Alnylam shepherding it with John through its evolution from bas...

Today we are talking to Joel Marcus. He has shaped the life sciences industry through ARE from the buildings we use to venture and fund investing. His impact can be directly seen in major cities across the US from Boston to NY to San Francisco ...

Today we are talking to Rachel Meyers. Rachel was most recently the CSO of Faze Medicines a company she launched with TRV to focus on the regulation of biomolecular condensates to treat disease. Prior to Faze she was an EIR at TRV prior to whic...

Today we are talking to Aofie Brennan, president and CEO of Synlogic. Aoife was trained as a doctor at Trinity College Dublin following which she moved to the US. After completing her postdoctoral research at Beth Israel Aofie joined TolerX foc...

Today we are talking to Drew Weissman. Drew is the Roberts Family Professor in Vaccine Research at Perelman School of Medicine and Director of the Penn Institute for RNA Innovation at the University of Pennsylvania. Drew has spent his career wo...

Today we are talking to Rodolphe Barrangou. Rodolphe is the Todd R Klaenhammer Distinguished Professor at NC State University. He is a scientist entrepreneur who has co-founded a multitude of biotech companies around CRISPR based approaches inc...

I am delighted to welcome back John Hoffman to Between the Biotech Waves. John is managing director & head of healthcare equity capital markets at Credit Suisse. In mid 2022 John joined the podcast to discuss the market outlook for ’22 and ...

I am delighted to welcome back Jim Birchenough to Between the Biotech Waves. Jim is Vice Chair Wells Fargo Biopharmaceutical Investment Banking. In 2022 Jim joined the podcast to discuss the market dynamics and learnings from prior market corre...

Today we are talking to Jeremy Levin. Jeremy is chairman and CEO of Ovid Therapeutics, focused on rare and orphan disease of the CNS. He is the immediate past chair of BIO. Jeremy has a storied career in biotech having served as pre...

Today we are talking to Laksh Aithani, Co-founder and CEO of Charm Therapeutics. Laksh is a scientist turned entrepreneur. He received his degree in Natural Sciences from the University of Cambridge. While at University he co-founded Genei, an ...

Today we are talking to Tom Barnes. Tom is CEO of Orna Therapeutics, a circular RNA focused biotech developing in situ CAR therapeutics. Orna recently announced a series B with a multi billion $ mega-deal with Merck. Prior to Orna Tom and I wor...

Today we are talking to JeanFrancois Formela. I have known JF for over 2 decades having worked with him at Atlas in building multiple biotech companies. JF is a partner at Atlas Venture which he joined in 1993 to build the US LS presence which ...

Today we are talking to Ram Aiyer. Ram is CEO of Korro Bio, an RNA base editing company focused on co-opting ADAR, a naturally present editing system in all our cells to base edit A to I (which is translated as a G) in RNA. Prior to Korro, Ram ...